Revenue (Tables)

12 Months Ended

Dec. 31, 2024

Revenue

Schedule of revenue recognized from collaborative arrangements

	Year Ended December 31,
(In thousands)	2024		2023
Viatris collaboration agreement – Amounts receivable from Viatris	$	64,381	$	57,201
Viatris royalties (Non-US)		—		7
Total	$	64,381	$	57,208

	Year Ended December 31,
(In thousands)	2024		2023
YUPELRI net sales (Theravance Biopharma implied 35%)	$	83,519	$	77,337

Summary of the reductions to R&D costs related to reimbursement payments

	Year Ended December 31,
(In thousands)	2024		2023
Viatris	$	407	$	5,723

Schedule of total revenue by geographic region

	Year Ended December 31,
(In thousands)	2024		2023
US	$	64,381	$	57,201
Europe		—		223
Total revenue	$	64,381	$	57,424

Schedule of total revenue from customers or collaboration partners who individually accounted for 10% or more of total revenue

	Year Ended December 31,
(% of total revenue)	2024		2023
Viatris	100	%	100	%